Tracey Winkworth
North London & East Anglia
Not a healthcare professional? Visit our Public site
Not a healthcare professional? Visit our Public site
has been added to your basket
59
Adverse event reporting information can be found at the bottom of this page
Summary of product characteristics & Patient information leaflet for 100 mg (GB)
Summary of product characteristics & Patient information leaflet for 150 mg (GB)
Summary of product characteristics & Patient information leaflet for 200 mg (GB)
Summary of product characteristics & Patient information leaflet (NI)
INDICATION
OMJJARA is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or UKSafety@gsk.com
March 2024 | PM-GB-MML-WCNT-230012 (V1.0)